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Methods: a search of the major databases was carried out to identify randomised controlled trials of intra-arterial
thrombolytic therapy in the treatment of limb ischaemia. The search was limited to English language articles, or those
that provided a sufficiently detailed English summary, and to articles published after 1980. In addition, key journals were
hand-searched and citations were also reviewed. Two reviewers independently performed data extraction and aggregate
outcomes were obtained using a random effects meta-analysis.
Results: a total of 34 articles were found, but only 10 were reports of randomised controlled trials. Meta-analysis showed
no significant differences between thrombolysis and surgery in terms of major amputation (relative risk (RR) 0.893 95%
confidence interval (CI) 0.576, 1.383) and mortality (RR 1.24 95% CI 0.795, 1.9). However, there was an increased risk
of haemorrhage with thrombolysis (RR 2.94 95% CI 1.1, 7.9). Sub-group analysis suggests that short-duration occlusions
(relative risk reduction (RRR) 72%, numbers needed to benefit (NNB)=3) and occluded grafts (RRR 58%, NNB=4)
may benefit from thrombolysis. However, thrombolysis should be avoided in occlusions of greater than 14 days –
particularly native vessel occlusions.
Conclusion: despite the theoretical advantages of thrombolysis, there is still insufficient evidence to justify its widespread
use except in graft occlusions and short-duration ischaemia.
Introduction were prospective randomised controlled trials (RCTs),
systematic reviews or meta-analysis – the latter two
Despite the obvious theoretical advantages of treating as a source of further trials.
Data extraction was performed independently byacute limb ischaemia with thrombolysis, its use re-
mains controversial and the evidence unclear. With two reviewers and cross-checked for accuracy. Ag-
gregate outcomes were obtained using a random-the recent publication of the TOPAS trial1 this debate
has acquired new stimulus. To try to gain a clearer effects meta-analysis.
picture of the evidence, a review of the evidence
for thrombolysis in the treatment of acute arterial
occlusions of the legs was performed.
ObjectivesThe major electronic databases (Medline, CINAHL,
Embase, Biological Abstracts, Science Citation Index To determine the relative effectiveness of intra-arterialand The Cochrane Library) were searched for ran- thrombolysis compared to surgery for the treatmentdomised controlled trials. The search was limited to of lower-limb ischaemia.English-language articles or articles that provided a
sufficiently detailed English summary of trial design
and results. The search was also limited to articles
published after 1980, as there was a great expansion Background
in the use of intra-arterial thrombolysis during that
decade.2 Trials were considered for inclusion if they Thrombolysis involves the use of a thrombolytic agent
to break down the fibrin contained within a thrombus.3
* The views in this document are those of the authors and not The three most commonly used substances are strepto-
necessarily those of the NHS Executive or the HTA Programme. kinase, urokinase and tissue plasminogen activator
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Road, Sheffield S5 7AU, U.K. the utilisation of a proenzyme, plasminogen, which is
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converted to an active thrombolytic enzyme, plasmin, review articles or case series or cohort studies (Tables
1 and 2).which breaks down fibrin.4
Thrombolysis has been used as a treatment for acute
arterial and graft occlusions for over 30 years, but
until the last 10 years there were no randomised
Description of Studiescontrolled trials to support its use.5 Thrombolysis al-
lows the option of restoring blood flow with only a
Surgery vs. thrombolysismildly invasive technique.6 However, threatment is
relatively expensive in terms of costs and resources.7
There were seven papers published which randomisedDespite the advantages of thrombolysis, there are
patients to either surgery or thrombolysis (see Datastill doubts regarding its safety and efficacy, as there
Extraction Tables 1 to 7, in the Appendix). The largestare risks of haemorrhage and the time to recanalise
studies were the STILE Trial10 and TOPAS Phase I6the affected artery is relatively long when compared
and II1.to surgical intervention.1 There was also little data on
The STILE Trial randomised a total of 393 patientsthe cost-effectiveness of thrombolysis when compared
to either surgical revascularisation or rt-PA or uro-to surgery with only two studies, both carried out in
kinase in a multicentre trial carried out in the U.S.A.the U.S.A., and both using hospital cost data.8,9
The initial design was for 1000 patients, but enrolment
stopped after the interim analysis because a significant
primary endpoint was reached when the results were
analysed.
The primary endpoint was a “composite clinicalMethods
outcome”, which was defined as the occurrence of an
adverse event. These events ranged in severity fromA search of major databases for randomised controlled
death/major amputation to postinterventional woundtrials (RCTs) related to thrombolysis was undertaken.
complications. There was also separate reporting ofThe search was limited to English-language articles or
mortality, amputation, ischaemia and life-threateningarticles that provided a sufficiently detailed English
haemorrhage. Analysis was by intention-to-treat andsummary of trial design and results. Hand-searching
so failure to place the catheter for thrombolysis in 28%of core journals and review of citations were also
of patients was considered a failure of treatment.performed following guidelines developed by the Bal-
Results showed that in the thrombolysis group theretimore Cochrane Centre.10
was greater risk at 1-month post treatment of:Trials were considered for inclusion if they were
prospective RCTs evaluating thrombolytic therapy. • Composite clinical outcome (55.2% (n=107) vs.
The quality of a trial was determined using a proforma 34.6% (n=44) (p=<0.001)).
based on the CONSORT statement33 and Cochrane • Ongoing/recurrent ischaemia (45.4% (n=88) vs.
Collaboration checklists.10 The proforma-graded stud- 23.6% (n=30) (p=<0.001)).
ies for inclusion by assessment of: • Life-threatening haemorrhage (6.2% (n=12) vs. 0.8%
(n=1) (p=0.019)).• Method of randomisation and degree of blinding. • Vascular complication (11.3% (n=22) vs. 3.1% (n=• Comparability of groups in control and intervention 4) (p=0.01)).arms at baseline.
• The analysis of results on an intention-to-treat basis. The mean length of hospital stay was less in the
• Completeness of follow-up. thrombolysis group (9.7 vs. 14.3 days (p=0.04)). How-
• The blinding and objectivity of outcome assessment. ever, there was no statistically significant difference
• The appropriateness and completeness of statistical between the two groups in terms of mortality (p=
analysis of results – including sensitivity analysis. 9.38) or major amputation (p=0.726).
The study also carried out sub-group analysis on
the basis of duration of ischaemia. At 1 month follow-
up patients with ischaemia of greater than 14 days in
the thrombolysis group had a greater risk of composite
clinical outcome (62.9% (n=107) vs. 29.2% (n=28)Results
(p<0.001)) and ongoing/recurrent ischaemia (58.2%
(n=99) vs. 20.8% (n=20) (p<0.001)). However, withA total of 34 papers were retrieved, and of these 10
were found to be RCTs. The other papers were either ischaemia of less than 14 days’ duration there were
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Table 2. Excluded studies. Weaver et al.12
This paper reported a sub-group of patients with non-Published trial Reason for exclusion
embolic native artery occlusions from the STILE trial.10
Allen et al.18 Review article This study showed that surgery was more effective
Braithwaite et al.19 Review article than thrombolysis. There was an increased risk of
Dawson et al.20 Retrospective study major amputation at 6 months in the thrombolysis
De-Felice et al.21 Review article group (6.7% (n=10) vs. 0% (p<0.05)) and 1 year (10%
Diffin et al.22 Review article (n=15) vs. 0% (p<0.05)). This was particularly pro-
Earnshaw et al.23 Retrospective cohort study nounced in the sub-group with femoral–popliteal ar-
Earnshaw JJ2 Review article tery occlusions with a greater risk of amputation with
Earnshaw JJ Review article thrombolysis at 6 months (8.7% (n=9) vs. 0% (p<0.005))
Gaines et al.4 Review article and 1 year (13.5% (n=14) vs. 0% (p=0.001)). In ad-
Golledge et al.3 Review article dition, patients with diabetes in the femoral–popliteal
Gonzaleez-Fajardo et al.25 Non-randomised study artery occlusion group who had surgical re-
Goodman et al.26 Cohort study vascularisation had a higher mortality rate at 30 days
Hess et al.27 Non-randomised study (16% vs. 0%, p=0.005), 6 months (25.8% vs. 1.9%, p=
Hicken et al.28 Cohort study 0.002) and 1 year (32% vs. 6%, p=0.014).
Hye et al.29 Retrospective study
Marcus et al.30 Cohort study TOPAS Phase I6
Meyerovitz et al.16 Small study (16 patients), A total of 213 patients were randomised to intra-
methodological problems arterial variable doses (2000 IU or 4000 IU or 6000 IU)
Ouriel et al.8 Economic study of rUrokinase or surgery. There were no statistically
Ouriel K31 Report of Ouriel et al. 199413 significant differences between surgery and throm-
Ouriel K32 Review article bolysis groups in terms of mortality, amputation-free
Pilger E33 Review article survival or incidence of haemorrhage. However, the
Van Breda et al.9 Economic study higher dose of urokinase (6000 IU) did experience more
haemorrhagic complications when compared to the
other dosages (p=0.031).
TOPAS Phase II1
This multi-centre trial randomised 548 patients withno statistically significant differences between surgery
acute limb ischaemia to either intra-arterial urokinaseand thrombolysis groups.
or surgery. There were some demographic differencesThe 6-month follow-up confirmed the benefits of
at baseline: the thrombolytic group had significantlythrombolysis for patients with ischaemia of less than
more men (p=0.046), patients with rest pain (p=0.003)14 days with a greater risk of major amputation in the
and patients with hepatic and renal insufficiency (p=surgery group (30% (n=12) vs. 11.1% (n=8) (p=0.02)).
0.027).There was also a higher risk of major amputation
There were no statistically significant differences inin the thrombolysis group (12.1% (n=21) vs. 3% (n=
amputation-free survival or mortality between throm-3) (p=0.01)) for those with ischaemia of greater than
bolysis and surgery groups at 6 months and 1 year. In14 days.
addition, there were no differences between the two
groups in length of stay (median 10 days for both
Comerota et al.11 groups) or ABPI (p=0.23) (see Data Extraction Table 5,
This paper reported the sub-group of patients who Appendix).
had occluded bypass grafts in the STILE trial.10 All There was, however, an increased risk of major
outcomes were at the 1 year follow-up. haemorrhagic complications in the thrombolysis group
Prosthetic grafts tended to have increased “major (12.5% (n=32) vs. 5.5% (n=14) (p=0.005)) and a sig-
morbidity” compared to autogenous grafts (p=0.04). nificant association between risk of haemorrhage and
There was confirmation of the benefit of thrombolysis co-administration of heparin (RR 2.19, p=0.02 95% CI
for acute ischaemia with an increased risk of major 1.13, 4.24).
amputation in the surgery arm of the trial (48% (n=
11) vs. 20% (n=7) (p=0.026)). However, there were Ouriel et al.13
A total of 119 patients were randomised, but analysisno statistically significant differences between the
groups for those with chronic ischaemia. was carried out for 114 in this single-centre trial per-
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formed in the U.S.A. Patients with less than 7 days’ statistical significance (p=0.04) at 8 h in successful
lysis in the rt-PA group, but not at the other timeduration of ischaemia were randomised to either intra-
arterial thrombolysis or surgery. The treatment groups points. There was no significant difference between
the groups in terms of clinical outcome.were “balanced” at baseline. The 30-day combined
mortality or amputation was greater in the surgical However, this trial was excluded on quality criteria.
The analysis was not intention-to-treat and the numbergroup (30% (n=17) vs. 14% (n=8) (p=0.04)). However,
there were no significant differences in separate mor- of patients who had arteriograms varied at the different
time points. For example: the initial number of 16 intality and amputation rates.
Kaplan–Meier estimate of event-free survival each treatment arm became 10 in the rt-PA group and
11 in the urokinase group at 8 h, at 16 h it was 1 inyielded a risk of limb loss or death for thrombolysis
of 25% vs. 48% for surgery (p=0.02). There was also a the rt-PA and 4 in the urokinase, and at 24 h it was 5
in the rt-PA and 10 in the urokinase group. This would62% reduction in the risk of death for the thrombolytic
group (survival was 84% for thrombolysis vs. 58% for lead to the results being open to bias.
surgery (p=0.01)).
Nilsson et al.14
This was a small single-centre study with only 20 Dosage of thrombolytic agent
patients randomised to either surgery (thrombectomy)
(n=9) or thrombolysis (IA rt-PA) (n=11). There were Only one trial, which directly compared this, was
no differences found between the two groups in the found: Braithwaite et al.5 This was a multicentre trial
rates of successful revascularisation. There were no carried out in the U.K. It randomised 100 patients,
incidences of mortality or major haemorrhage. with acute leg ischaemia of less than 30 days, to intra-
arterial thrombolysis with either high-dose bolus rt-
PA (3·5 mg bolus doses then 3.5 mg/h for up to 4 h
and then 0.5–1.0 mg/h) or low-dose rt-PA (0.5–1.0 mg/
h). Analysis was not by intention-to-treat, as sevenMode of administration
were excluded post-randomisation as they “violated
the protocol conditions”.There was only one study found which examined
There were no statistically significant differencesthis, which was Berridge et al.15 They randomised 60
between the two groups in terms of 30-day limbpatients to either intra-arterial (IA) streptokinase or
salvage or complication rates. However, the patientsintra-arterial rt-PA or intravenous rt-PA. The trial was
in the high-dose group had more adjunctive pro-multicentre and included “many centres”, but no de-
cedures and vascular reconstructions (26 vs. 16, p=tails of number or location were given in the paper.
0.002).Radiological success: IA rt-PA achieved greater com-
plete or partial success than the other groups (p<0.04).
However, both IA rt-PA and IA streptokinase achieved
complete success in 85% (n=17) and 80% (n=16),
respectively, compared with only 30% (n=6) for IV
Meta-analysis resultsrt-PA.
The 3-month limb-salvage rate did not achieve stat-
Aggregate outcomes were obtained using a random-istical significance between the groups.
effects method of meta-analysis. This method takes
into account possible intra- and inter-study hetero-
geneity. Heterogeneity was tested using the Chi-
squared test at a significance level of p<0.1 due to the
relative insensitivity of this test method.Type of thrombolytic agent
All of the meta-analysis plots for thrombolysis vs.
surgery (Figs 1–7) show that there appeared to be noOnly one trial was found which directly compared
two thrombolytic agents: Meyerovitz et al.16 The sample difference between surgery and thrombolysis in terms
of mortality and amputation. However, the aggregatesize was small, with 16 randomised to either intra-
arterial rt-PA or urokinase. The main outcome measure odds ratio for major haemorrhage showed an increased
risk for thrombolysis of 195% (OR=2.95 (p<0.001 95%was 95% or greater thrombolysis, as determined by
serial arteriograms at 4, 8, 16 and 24 h. The trial found CI 1.62, 5.36)).
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Odds ratio 1.0 20.5 0.70.3
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Stile Trial
1.0
Surgery
Ouriel
Total
Odds ratio
Thrombolysis
2.949, p < 0.001*
Topas2
40302010
Fig. 1. Major amputation: 30 days. Log of Odds Ratio, random Fig. 3. Risk of major haemorrhage – 30 days. *Cochrane Q het. p=
0.39.effects model. *Cochrane Q heterogenicity (Cochrane Q het.) p=
0.40.
3
Stile
0.3
Surgery
Topas II
Total
Odds ratio 0.8 20.4 0.6
Thrombolysis
1.0
1.111, p = 0.72*
0.2
Fig. 4. Risk of mortality – 6 months. *Cochrane Q het. p=0.32.
4
Topas2
0.2
Surgery
Ouriel
Total
Odds ratio 1.0 20.6 0.8
Thrombolysis
0.4
1.077, p = 0.78*
3
Stile Trial
0.3
Fig. 2. Risk of mortality – 30 days. *Cochrane Q het. p=0.38.
group compared to surgery was 0.41, i.e. there was a
59% greater chance of mortality/amputation for the
surgical group.
There were two other sub-groups analysed withinDiscussion
the STILE trial, native12 and graft11 occlusions. For
native artery occlusions the analysis showed that thereThe results of the literature search have highlighted the
lack of large randomised controlled trials evaluating was a greater risk of major amputation in the throm-
bolysis group, except for patients with iliac–commonthrombolysis vs. surgical management. The two largest
trials in this area are the STILE10 and the TOPAS6 femoral artery occlusions, where there was no dif-
ference between surgery and thrombolysis. For grafttrials.1 The relative risks (RR) and numbers needed to
treat (NNT) for the key findings of the published occlusions, thrombolysis increased the risk of on-
going/recurrent ischaemia (RR 1.46), but there werearticles are shown in Table 3.
The STILE Trial10 showed that there was no dif- no differences between the groups in terms of mortality
or amputation rates. The exception to this were patientsference between surgery and thrombolysis in terms of
mortality or risk of amputation. However, it did show with ischaemia of less than 14 days, who had a greater
risk of amputation in the surgical group (RR=0.42),that there was an increased risk within the throm-
bolysis group as a whole of morbidity (RR=1.70 95% with thrombolysis showing a relative risk reduction
for amputation of 58%.CI 1.34, 2.16), ongoing/recurrent ischaemia (RR=2.1
95% CI 1.55, 2.83) and haemorrhage (RR=8.1 95% CI The TOPAS Phase I study6 appeared to show that
the dosage of urokinase with the least risk haem-1.10, 60.96) – when compared to surgery. However,
sub-group analysis by duration of ischaemia showed orrhage was 4000 IU/min. There were no significant
differences between the different dosages and surgerythat for ischaemia less than 14 days the relative risk
(RR) of mortality/amputation for the thrombolysis in terms of mortality and amputation. The TOPAS
Eur J Vasc Endovasc Surg Vol 19, February 2000
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3
Stile
0.5
Surgery
Topas II
Total
Odds ratio 1.0 20.70.8
Thrombolysis
0.6
1.183, p = 0.38*
3
Topas II
0.3
Surgery
Ouriel
Total
Odds ratio 1.0 20.6 0.80.5
Thrombolysis
0.4
1.145, p = 0.49*
Fig. 5. Risk of major amputation – 6 months. *Cochrane Q het. p= Fig. 7. Risk of major amputation – 12 months. *Cochrane Q het.
p=0.76.0.88.
problems. Furthermore, such a large number of centres
with resultant variations in practice and setting means
that there could be doubts about the external validity
of the trial.
Ouriel et al.13 found that there was a decreased risk
of amputation or death at 1 year in the thrombolysis
group (RR 0.47) and the cumulative survival rate was
greater in the thrombolysis group. However, this study
only included acute limb ischaemia of less than 7 days.
It does appear to confirm the benefits of thrombolysis
for patients with limb ischaemia of short duration.
7
Ouriel
0.0
Surgery
Topas II
Total
Odds ratio 2 40.3 1.0
Thrombolysis
0.589, p = 0.49*
Nilson et al.14 was a small study of only 20 patients
Fig. 6. Risk of mortality – 12 months. *Cochrane Q het. p=0.32. and failed to detect any significant differences between
surgery and thrombolysis – which was probably due
to an inadequate sample size.Phase II study1 found no differences between surgery
and thrombolysis in terms of amputation, mortality, Berridge et al.15 achieved greater success with intra-
arterial administration at the site of the thrombuslength of stay, and ABPI, but there was a greater risk
of haemorrhage in the thrombolysis group (RR=2.29 rather than systemic intravenous administration. How-
ever, the trial was relatively small (n=60) and the95% CI 1.3, 4.2). There also appeared to be an increased
risk of haemorrhage with the therapeutic use of hep- sample size was probably not sufficient to detect dif-
ferences between the two groups on all the outcomearin (RR 2.19 p=0.02 95% CI 1.13, 4.24).
Both the STILE and TOPAS trials have some method- measures included.
Braithwaite et al.5 compared high-dose and con-ological flaws. The STILE trial originally aimed to
recruit 1000 patients based on sample size calculations, ventional low-dose regimes for IA rt-PA ad-
ministration. The trial suggested benefits of the highbut recruitment was stopped after 393 due to a “sig-
nificant primary endpoint occurring at the interim dose in terms of reduced duration of infusion, but
there were a greater number of adjunctive proceduresanalysis”. This could mean that the trial’s power will be
reduced in detecting significant differences, especially compared to the low-dose group. However, the trial
did not analyse by intention-to-treat and the studywithin the sub-group analysis. In addition, throm-
bolysis patients were randomised to either rt-PA or admits to not having sufficient power.
The overall impression provided by this review isurokinase, but the results for thrombolysis were ana-
lysed by pooling these two groups. The TOPAS Phase that thrombolysis does not provide benefit for the
whole patient population presenting with limb isch-II study’s main flaw was the large number of centres
contributing to the study compared with the total aemia. The published trials do show that there could
be sub-groups of patients who would benefit fromnumber of patients included in the study – there were
113 centres involved in the study and 548 patients thrombolysis compared to surgery. The patients who
would benefit the most are those with acute ischaemiarecruited. The limited number of patients recruited at
each centre could indicate selection bias or recruitment of less than 14 days’ duration and those with acute
Eur J Vasc Endovasc Surg Vol 19, February 2000
S. J. Palfreyman et al.150
Table 3. Relative risk and numbers needed to benefit or harm.
STILE Trial Relative risk Relative risk reduction Numbers needed to harm
(NNH)/numbers needed to
benefit (NNB)
Composite clinical outcome 1.70 (1.34, 2.16) -66% NNH=4 (95% CI 3, 6)
(1 month)
Recurrent ischaemia (1 month) 2.1 (1.55, 2.83) -110% NNH=4 (95% CI 4, 5)
6 month outcomes
Mortality/amputation 0.98 (0.62, 1.53) 2% NNB=204 (95% CI-13, 13)
Amputation ischaemia <14 days 0.37 (0.17, 0.83) 72% NNB=5 (95% CI 3, 35)
Amputation ischaemia >14 days 4.06 (1.24, 13.29) -306% NNH=12 (95% CI 7, 37)
Sub-group occluded grafts
Composite clinical outcome 1.8 (1.34, 2.42) -80% NNH=4 (95% CI 3, 33)
(1 month)
Ongoing/recurrent ischaemia 1.7 (1.06, 2.81) -46% NNH=5 (95% CI 3, 21)
(1 month)
Duration of ischaemia <14 days 0.42 (0.20, 0.92) 58% NNB=3 (95% CI 2, 25)
Major amputation (1 year)
Duration of ischaemia >14 days 1.2 (0.35, 4.27) 20% NNH=100 (95% CI-7, 6)
Major amputation (1 year)
Duration of ischaemia >14 days 1.98 (1.77, 3.34) -98% NNH=3 (95% CI 2, 6)
Ongoing/recurrent ischaemia
(1 month)
Sub-group native artery occlusions
Composite clinical outcome 1.8 (1.34, 2.42) -80% NNH=4 (95% CI 3, 6)
Major amputation (6 months) (Cannot calculate event rate 0 – NNH=16 (95% CI 8, 50)
in surgery group)
Major amputation (1 year) – – NNH=10 (95% CI 7, 20)
Ongoing recurrent ischaemia 2.3 (1.60, 3.42) -130% NNH=3 (95% CI 2, 5)
TOPAS II
Major haemorrhagic complications 2.29 (1.25, 4.20) -129% NNH=14 (95% CI 10, 50)
Ouriel et al.
Mortality or death (6 months) 0.74 (0.52, 1.06) 53% NNB=10 (95% CI-4, 14)
Mortality or death (12 months) 0.74 (0.2, 2.7) 53% NNB=6 (95% CI-3, 50)
bypass graft occlusions. Furthermore, there are sub- workload.36 The risks and benefits of thrombolysis
have to be assessed by surgeons, radiologists andgroups, chronic ischaemia and chronic graft oc-
clusions, where thrombolysis should be avoided due patients, as thrombolysis appears to be of benefit to a
small sub-group of the whole population of patientsto an increased risk of amputation.
However, these conclusions are based on sub-group with limb ischaemia. If thrombolysis is attempted and
is not successful, then there need to be facilities andanalysis of the population within larger trials. There-
fore, they should not be classified as definitive due to expertise for other treatment options.
the sample sizes in some of the groups being relatively
small, and so having reduced power to detect dif-
ferences. Conclusion
The results of this review largely confirm the con-
clusions of a recently published consensus document The main conclusion that can be drawn from the trials
is that thrombolysis should not be given to everyon the thrombolytic management of lower limb arterial
occlusion.34 However, our review does emphasise the patient who presents with lower-limb ischaemia and
should be viewed as an adjunct to other treatments.current lack of high-quality evidence on which to
base a consensus. There does need to be a careful Sub-group analysis for the trials suggests that throm-
bolysis should be avoided in occlusions of greater thanassessment, by expert practitioners, of each individual
case history and radiological evidence to ensure that 14 days – particularly native vessel occlusions, as the
risks outweigh the benefits. However, it also suggeststhere is a balance between the potential harm and
benefit of thrombolysis. that short-duration occlusions of grafts may benefit
from thrombolysis. These conclusions are based onThe nature of leg ischaemia means that the best
results of treatment are likely to be in centres offering sub-group analysis and so what is urgently required
are new trials, of sufficient sample size, to confirm ora full range of services with co-operation between
vascular surgeons and radiologists,35 and with a high deny these results.
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APPENDIX
Search Strategy MEDLINE
1 Exp “Thrombolytic therapy”
2 Exp “streptokinase”/or exp “urokinase”/or exp “tissue plasminogen activator”
3 1 or 2
4 Limit 3 to yr=1980–1998
5 Limit 4 to clinical trial
6 Exp “Ischemia”
7 5 and 6
8 “acute” or “limb” or “legs” or “limbs” or “extremit*” in ti, ab, rw, sh
9 7 and 8
10 Limit 9 to English language and randomized controlled trial
11 “limb” or “leg” or “legs” or “limbs” or “extremit*” in ti, ab, rw, sh
12 7 and 11
13 Exp “Plasminogen activators”
14 6 and 11 and 13
15 Limit 14 to English language and clinical trial
Search Strategy EMBASE
1 “FIBRINOLYTIC-THERAPY”/all subheadings
2 STREPTOKINASE
3 UROKINASE
4 “TISSUE PLASMINOGEN-ACTIVATOR”/all subheadings
5 1 or 2 or 3 or 4
6 ISCHEM*
7 ISCHAEM*
8 ISCHEM* or ISCHAEM*
9 5 and 8
10 LA=“ENGLISH”
11 9 and (LA=“ENGLISH”)
12 LIMB
13 LIMBS
14 LEG
15 LEGS
16 EXTREMIT*
17 LIMB or LIMBS or LEG or LEGS or EXTREMIT*
18 11 and 17
19 TRIAL*
20 RANDOM*
21 CONTROL*
22 TRIAL* or RANDOM* or EXTREMIT*
23 MAJOR-CLINICAL-STUDY
24 22 or 23
25 18 and 24
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Data Extraction Table 4.
Trial ID Participants: sample Interventions Baseline Results Withdrawals Comments
and setting comparability
Ouriel et al. (TOPAS I1a: 2000 IU/min
Phase I)6 No randomised: 213 urokinase (n=45) There were no Analysis by intention- I1a: 3
U.S.A. I1b: 4000 IU/min significant to-treat I1b: 3
Multicentre Inclusion criteria: urokinase (n=49) differences between I1c: 5
Patients with acute I1c: 6000 IU/min the groups at Severe or life- I2: 4
Method of lower limb peripheral (n=50) baseline threatening
randomisation: artery occlusion of less I2: Surgery (n=59) haemorrhage:
Centralised than 14 days duration, Mean age: I1a: 6
randomisation thromboses or embolic I1a: 66.2–1.9 I1b: 1
centre. Stratified by aetiology I1b: 62.2–1.8 I1c: 8
whether occlusion I1c: 62.5–1.8 I2: Not given
native artery or Exclusion criteria: I2: 66.5–1.8 p=0.031 for I1b vs. I1c
bypass graft. Contraindication to p=1.82
surgery or Mortality:
Outcomes: thrombolysis, systolic % Male: No statistically
Haemorrhage >180, CVA within 6 I1a: 70.7% significant differences
Mortality months, TIA within 2 I1b: 74.4% between the groups
Amputation-free months, life I1c: 76.1% (p>0.05) but appeared
survival expectancy <1 year I2: 66.5% to be least in 4000 IU
p=0.476 group
Setting and length of Amputation-free
follow-up: survival:
30 days, 6 months No statistically
and 1 year significant differences
between the groups
Data Extraction Table 5.
Trial ID Participants: sample Interventions Baseline Results Withdrawals Comments
and setting comparability
Ouriel et al. (TOPAS No participants: 548 Sex: Analysis by intention
Phase II)1 I1: IA Urokinase Male: to treat Total of 33 patients’ Very large number of
Multicentre (n=113) (n=272) I1: 71% post-randomisation participating centres!
U.S.A. and Europe Inclusion criteria: I2: 62% Amputation-free No breakdown of how
Acute thrombotic or I2: Surgery (n=272) p=0.046 survival many patients
Method of embotic occlusion of 6 months: contributed by each
randomisation: less than 14 days Rest pain: I1: 71.8% centre.
Randomisation duration I1: 78% I2: 74.8%
centre. Stratification I2: 66% p=0.43
by native artery or Exclusion criteria: p=0.003
bypass graft. Contraindication for 1 year:
surgery or Hepatic/renal I1: 65%
Objective outcome: thrombolysis, insufficiency: I2: 69.9%
Amputation-free pregnancy or chance I1: 21% p=0.23
survival at 6 months of pregnancy I2: 14%
and 1 year p=0.027 Mortality, length of
Complications stay and ABPI:
ABPI Other parameters No statistically
were similar at significant difference
baseline at 6 months or 1 year
Setting and length of
follow-up: Major haemorrhagic
Hospital complications:
6 months and 1 year I1: 12.1% (n=32)
I2: 5.5% (n=14)
p=0.005
Data Extraction Table 6.
Trial ID Participants: sample Interventions Baseline Results Withdrawals Comments
and setting comparability
Ouriel13 No participants:
U.S.A. 119 randomised but I1: Thrombolysis “Balanced” Kaplan–Meier 5 post-randomisation There was decreased
Single centre 114 analysed (intra-arterial) (n=57) treatment groups analysis event-free mortality in
but no p values survival 12 months thrombolysis group
I2: Surgery (n=57) given and it should be used
Method of Inclusion criteria: Thrombolysis=75% as the initial
randomisation: Acute limb ischaemia Concurrent vs. 52% (p=0.02), i.e. intervention for ALI
Computer generated <7 days duration interventions: thrombolysis=48%
randomisation list None reduction in the 1 year
Exclusion criteria: risk of amputation or
Objective outcome: Contraindication for death
Mortality thrombolysis or
Limb salvage operative Cumulative survival
Major complications revascularisation or rate greater in
LOS arteriography and thrombolysis group
pregnancy (84% vs. 58% at 1 year)
(p=0.01)
Length of follow-up:
Mean 20.5 months
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Data Extraction Table 7.
Trial ID Participants: sample Interventions Baseline Results Withdrawals Comments
and setting comparability
Nilsson et al.14 No participants: 20 Sex: One from lysis group Small study with
Sweden I1: Surgery I1: 5 male, 4 female Successful (I2) samples size
Single centre trial Inclusion criteria: (thrombectomy) (n=9) I2: 8 male, 3 female revascularisation inadequate to detect
Ischaemia of leg with a No significant any differences
Method of duration of greater I2: Thrombolysis (IA Duration of difference between the between the two
randomisation: than 24 h but less than rt-PA) (n=11) symptoms: two groups treatments
Not stated 14 days I1: 2.9 days (1–7)
I2: 6.3 days (1–14) No incidence of
Objective outcome: Exclusion criteria: mortality or major
Successful Systolic BP >200, CVA morbidity in either
revascularisation within 6 months, group
Complications surgery within
Mortality previous 3 weeks,
peptic ulcer or current
Setting and length of treatment with
follow-up: anticoagulants
30 days
Data Extraction Table 8.
Trial ID Participants: sample Interventions Baseline Results Withdrawals Comments
and setting comparability
Berridge et al.15 No participants: 60
U.K. I1: IA Streptokinase No significant Radiological success: None stated Small trial. Sample
Single-centre trial (n=20) differences found I1: Complete 16, size not sufficient to
Inclusion criteria: at baseline Partial 0 detect differences
Sudden onset or I2: IA rt-PA (n=20) % Total=80% between groups.
Method of deterioration of
randomisation: peripheral limb I3: IV rt-PA (n=20) I2: Complete 17,
Not stated ischaemia of less than Partial 3
30 days duration % Total=100%
Outcomes: sufficient to cause
Radiological success critical ischaemia I3: Complete 6, Partial 3
ABPI % Total=45%
Limb salvage rates Exclusion criteria:
Complications Embolic aetiology, % Total p value=0.04
child bearing potential,
Setting and length of CVA within 2 months, 3-month limb salvage
follow-up: contraindication to rate:
Hospital thrombolysis, arterial This did not achieve
3 months thrombus causing statistical significance
severe ischaemia with I1: 60% (n=12)
good run-off I2: 75% (n=15)
I3: 50% (n=10)
Data Extraction Table 9.
Trial ID Participants: sample Interventions Baseline Results Withdrawals Comments
and setting comparability
Braithwaite et al.5 No participants: 100 Analysis excluded Study did not have
U.K. I1: High dose IA rt-PA No significant withdrawals: Seven in total sufficient power to
Multi-centre trial (3·5 mg over 30 min differences found I1: 1 detect differences in
Inclusion criteria: plus 3.5 mg/h for 4 h, at baseline 30 day limb salvage I2: 6 secondary endpoints
Patients over 18 with then 0.5–1.0 mg/h) rate or complication rates
Method of sudden onset (n=49) I1: 39 (78% ITT) Reasons:
randomisation: unilateral leg I2: 37 (74% ITT) 1 duration of
Not stated ischaemia for whom I2: Conventional low p=0.58 ischaemia >30 days
thrombolysis dose rt-PA 1 pt moribund
Outcomes: considered as a (0.5–1.0 mg/h) (n=44) Median duration of 1 collapsed graft
Duration of infusion treatment option, infusion 4 thrombolysis
Successful duration of less than I1: 4 h (range 1–46) infusions did not
thrombolysis 30 days, native and I2: 20 h (range 2–46) adhere to protocol
Complications graft occlusions p<0.0001
Adjunctive eligible
procedures Complications
Exclusion criteria: No significant
Setting and length of Contraindication for differences between
follow-up: thrombolysis due to the groups
Hospital CVA within 2 months,
3 months pregnancy, child Adjunctive procedures
bearing age, patients I1: 26
with total (white leg) I2: 16
ischaemia p=0.002
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